Vanguard Files Schedule 13G/A: 10.89% Ownership in Sarepta Therapeutics

Rhea-AI Filing Summary

The Vanguard Group filed Amendment No. 11 to Schedule 13G for Sarepta Therapeutics, Inc. (SRPT), reporting ownership of 10,641,733 shares, equal to 10.89% of the outstanding common stock. Vanguard reports 0 sole voting power, 606,072 shared voting power, 9,925,846 sole dispositive power, and 715,887 shared dispositive power. The filing states these shares are held in the ordinary course of business and are not intended to influence control of the issuer. The filing identifies Vanguard's Malvern, PA address and is signed by Ashley Grim, Head of Global Fund Administration, dated 09/08/2025.

Positive

• Material institutional ownership disclosed: Vanguard holds 10.89% of SRPT, providing clear transparency on a major shareholder.
• Passive intent declared: Filing certifies shares are held in the ordinary course and not to influence control, reducing immediate governance uncertainty.

Negative

• Concentrated stake: A single institutional holder reporting 10.89% represents a sizable ownership concentration that could affect trading liquidity or vote dynamics.
• Limited voting clarity: Vanguard reports 0 sole voting power and only 606,072 shared voting power, which may complicate predictions of how votes will be cast across managed accounts.

Insights

Securities Analyst

TL;DR: Vanguard holds a material passive stake of 10.89% in SRPT, disclosed as non-control and held in the ordinary course.

Vanguard's reported 10,641,733 shares (10.89% of the class) is a significant institutional position that should be viewed as a large passive ownership stake rather than an active control attempt. The breakdown shows substantial sole dispositive power (9,925,846 shares) with no sole voting power recorded, indicating voting decisions may be dispersed across managed accounts or delegated. For investors, this confirms a major index/asset-manager ownership profile without an expressed intent to change company control.

Corporate Governance Expert

TL;DR: A 10.89% filing by Vanguard signals concentrated institutional ownership but explicitly denies any control purpose.

The certification states the holdings are "acquired and held in the ordinary course of business" and "not for the purpose of changing or influencing control," aligning with a Schedule 13G passive disclosure. The combination of shared voting power (606,072) and predominately dispositive authority suggests Vanguard primarily manages economic exposure rather than exercising unilateral voting control. This is a routine, material disclosure for governance transparency.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 11)

Sarepta Therapeutics Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

803607100

(CUSIP Number)

08/29/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 803607100

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 606,072.00
7	Sole Dispositive Power 9,925,846.00
8	Shared Dispositive Power 715,887.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10,641,733.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.89 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Sarepta Therapeutics Inc
(b)	Address of issuer's principal executive offices: 215 First Street, Suite 415, Cambridge, MA, 02142
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd., Malvern, PA 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 803607100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 10641733
(b)	Percent of class: 10.89 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 606072
	(iii) Sole power to dispose or to direct the disposition of: 9925846
	(iv) Shared power to dispose or to direct the disposition of: 715887
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	09/08/2025

FAQ

How many SRPT shares does The Vanguard Group report owning?

The filing reports Vanguard beneficially owns 10,641,733 shares of SRPT, representing 10.89% of the class.

Does Vanguard state it intends to influence control of Sarepta (SRPT)?

No. The certification states the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

What voting and dispositive powers does Vanguard report for SRPT shares?

Vanguard reports 0 shares with sole voting power, 606,072 shared voting power, 9,925,846 sole dispositive power, and 715,887 shared dispositive power.

When was this Schedule 13G/A signed and by whom?

The statement is signed by Ashley Grim, Head of Global Fund Administration, with the signature date 09/08/2025.

What address is listed for The Vanguard Group in the filing?

The filing lists Vanguard's principal business address as 100 Vanguard Blvd., Malvern, PA 19355.